Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 1
1986 2
1988 1
1989 2
1990 3
1991 1
1993 3
1994 1
1995 3
1996 2
1998 1
2000 2
2001 1
2003 3
2004 4
2005 3
2006 1
2007 2
2008 3
2009 3
2010 2
2011 10
2012 2
2013 6
2014 4
2015 3
2016 7
2017 7
2018 6
2019 5
2020 5
2021 12
2022 13
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
Albinger N, Pfeifer R, Nitsche M, Mertlitz S, Campe J, Stein K, Kreyenberg H, Schubert R, Quadflieg M, Schneider D, Kühn MWM, Penack O, Zhang C, Möker N, Ullrich E. Albinger N, et al. Blood Cancer J. 2022 Apr 13;12(4):61. doi: 10.1038/s41408-022-00660-2. Blood Cancer J. 2022. PMID: 35418180 Free PMC article.
In the last years, immune-directed therapies such as chimeric antigen receptor (CAR)-T cells were introduced, which showed outstanding clinical activity against B-cell malignancies including acute lymphoblastic leukemia (ALL). ...Here we report on the …
In the last years, immune-directed therapies such as chimeric antigen receptor (CAR)-T cells were introduced, which showed out …
CAR-NK Cells in the Treatment of Solid Tumors.
Wrona E, Borowiec M, Potemski P. Wrona E, et al. Int J Mol Sci. 2021 May 31;22(11):5899. doi: 10.3390/ijms22115899. Int J Mol Sci. 2021. PMID: 34072732 Free PMC article. Review.
CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of patients with refractory B-cell neoplasms. ...CAR-NK cells are known to be effective against hematological malignancies, and a growing number of preclinical findings ind …
CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of patients with refractory B-cell neop …
DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer.
Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X, Liang K, Luo Y, Che K, Wang X, Pan Y, Liu F, Yang J, Liu Q, Yu L, Liu B, Wei J. Shi T, et al. Cancer Immunol Res. 2022 Dec 2;10(12):1506-1524. doi: 10.1158/2326-6066.CIR-22-0218. Cancer Immunol Res. 2022. PMID: 36206576
Results from in vitro coculture assays suggested that DKK1 induces macrophages to become immunosuppressive, thereby inhibiting antitumor responses of CD8+ T cells and natural killer (NK) cells. In vivo DKK1 blockade in syngeneic gastric cancer mouse mo …
Results from in vitro coculture assays suggested that DKK1 induces macrophages to become immunosuppressive, thereby inhibiting antitumor res …
The present and future of immunocytokines for cancer treatment.
Gout DY, Groen LS, van Egmond M. Gout DY, et al. Cell Mol Life Sci. 2022 Sep 6;79(10):509. doi: 10.1007/s00018-022-04514-9. Cell Mol Life Sci. 2022. PMID: 36066630 Free PMC article. Review.
However, solid tumors reduce the efficacy of mAb therapy because of an immune-suppressive tumor micro-environment (TME), which hampers activation of effector immune cells. ...Antibody-cytokine fusion proteins, also referred to as immunocytokines, provi …
However, solid tumors reduce the efficacy of mAb therapy because of an immune-suppressive tumor micro-environment (TME), which …
Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA/mRNA tumor vaccine.
Ma S, Li X, Mai Y, Guo J, Zuo W, Yang J. Ma S, et al. Acta Biomater. 2023 Oct 1;169:489-499. doi: 10.1016/j.actbio.2023.07.059. Epub 2023 Aug 2. Acta Biomater. 2023. PMID: 37536492
After nasal administration, the mLPR vaccine stimulated the maturation of dendritic cells, reprogramed M2 macrophages into M1 macrophages, as well cross-activated innate and adaptive immune responses. The mLPR vaccine inhibited the development of lung cancer and …
After nasal administration, the mLPR vaccine stimulated the maturation of dendritic cells, reprogramed M2 macrophages into M1 macroph …
Immune reactivity during COVID-19: Implications for treatment.
Napoli C, Benincasa G, Criscuolo C, Faenza M, Liberato C, Rusciano M. Napoli C, et al. Immunol Lett. 2021 Mar;231:28-34. doi: 10.1016/j.imlet.2021.01.001. Epub 2021 Jan 6. Immunol Lett. 2021. PMID: 33421440 Free PMC article. Review.
Also, patients with mild to severe COVID-19 displayed macrophage activation syndrome (MAS), very low human leukocyte antigen D related (HLA-DR) expression with a parallel reduction of CD04(+) lymphocytes, CD19 lymphocytes, and natural killer (NK) cells …
Also, patients with mild to severe COVID-19 displayed macrophage activation syndrome (MAS), very low human leukocyte antigen D relate …
Hemophagocytic lymphohistiocytosis: pathogenesis and treatment.
Janka GE, Lehmberg K. Janka GE, et al. Hematology Am Soc Hematol Educ Program. 2013;2013:605-11. doi: 10.1182/asheducation-2013.1.605. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319239 Review.
Genetic defects in familial HLH and in immunodeficiency syndromes associated with albinism affect the transport, processing, and function of cytotoxic granules in natural killer cells and cytotoxic T lymphocytes. This leads to defective killing of target c …
Genetic defects in familial HLH and in immunodeficiency syndromes associated with albinism affect the transport, processing, and function of …
Evidence-Based Review of BioBran/MGN-3 Arabinoxylan Compound as a Complementary Therapy for Conventional Cancer Treatment.
Ooi SL, McMullen D, Golombick T, Nut D, Pak SC. Ooi SL, et al. Integr Cancer Ther. 2018 Jun;17(2):165-178. doi: 10.1177/1534735417735379. Epub 2017 Oct 17. Integr Cancer Ther. 2018. PMID: 29037071 Free PMC article. Review.
INTRODUCTION: Conventional cancer treatment, including surgery, chemotherapy, and radiotherapy, may not be sufficient to eradicate all malignant cells and prevent recurrence. Intensive treatment often leads to a depressed immune system, drug resistance, and toxicity, hampe …
INTRODUCTION: Conventional cancer treatment, including surgery, chemotherapy, and radiotherapy, may not be sufficient to eradicate all malig …
Genetic engineering of porcine endothelial cell lines for evaluation of human-to-pig xenoreactive immune responses.
Li P, Walsh JR, Lopez K, Isidan A, Zhang W, Chen AM, Goggins WC, Higgins NG, Liu J, Brutkiewicz RR, Smith LJ, Hara H, Cooper DKC, Ekser B. Li P, et al. Sci Rep. 2021 Jun 23;11(1):13131. doi: 10.1038/s41598-021-92543-y. Sci Rep. 2021. PMID: 34162938 Free PMC article.
We developed an efficient approach to quickly examine human-to-pig xeno-immune responses in vitro. A porcine endothelial cell was characterized and immortalized for genetic modification. Five genes including GGTA1, CMAH, beta4galNT2, SLA-I alpha chain, and beta2-microglobu …
We developed an efficient approach to quickly examine human-to-pig xeno-immune responses in vitro. A porcine endothelial cell was cha …
Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses.
Mylod E, McKenna E, Davern M, Barr MP, Donlon NE, Bibby BAS, Bhardwaj A, Reynolds JV, Lysaght J, Maher SG, Conroy MJ. Mylod E, et al. Clin Exp Med. 2023 Jun;23(2):411-425. doi: 10.1007/s10238-022-00811-6. Epub 2022 Apr 1. Clin Exp Med. 2023. PMID: 35364779 Free PMC article.
Natural killer receptor (NKR) ligand expression by OE33CisP (cisplatin-sensitive) and OE33CisR (cisplatin-resistant) cells was investigated. ...Overall, OE33CisR cells express less activating NKR ligands than OE33CisP cells and have diffe …
Natural killer receptor (NKR) ligand expression by OE33CisP (cisplatin-sensitive) and OE33CisR (cisplatin-resistant) cells …
123 results